Difference between revisions of "Carboplatin (Paraplatin)"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
===Calvert formula=== | ===Calvert formula=== | ||
* Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. [https://doi.org/10.1200/jco.1989.7.11.1748 link to original article] '''contains verified formula''' [https://pubmed.ncbi.nlm.nih.gov/2681557 PubMed] | * Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. [https://doi.org/10.1200/jco.1989.7.11.1748 link to original article] '''contains verified formula''' [https://pubmed.ncbi.nlm.nih.gov/2681557 PubMed] | ||
| + | |||
| + | ==Diseases for which it is established== | ||
| + | *[[Malignant pleural mesothelioma]] | ||
| + | *[[Ovarian cancer]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 33: | Line 37: | ||
*[[Medulloblastoma]] | *[[Medulloblastoma]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
| − | |||
*[[Nasopharyngeal carcinoma]] | *[[Nasopharyngeal carcinoma]] | ||
*[[Neuroblastoma]] | *[[Neuroblastoma]] | ||
| Line 40: | Line 43: | ||
**[[Non-small cell lung cancer, squamous]] | **[[Non-small cell lung cancer, squamous]] | ||
*[[Osteosarcoma]] | *[[Osteosarcoma]] | ||
| − | |||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
Revision as of 00:26, 26 May 2022
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Dosing information
Calvert formula
- Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. link to original article contains verified formula PubMed
Diseases for which it is established
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Anal cancer
- Anaplastic glioma
- Bladder cancer
- Breast cancer
- Cervical cancer
- Diffuse large B-cell lymphoma
- Endometrial cancer
- Esophageal cancer
- Ewing sarcoma
- Extranodal NK- and T-cell lymphoma, nasal type
- Gastric cancer
- Glioblastoma
- Head and neck cancer
- Hodgkin lymphoma
- Low-grade glioma
- Mantle cell lymphoma
- Medulloblastoma
- Melanoma
- Nasopharyngeal carcinoma
- Neuroblastoma
- Non-small cell lung cancer
- Osteosarcoma
- Prostate cancer
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Unknown primary
- Upper tract urothelial carcinoma
Diseases for which it was used
Patient drug information
- Carboplatin (Paraplatin) package insert
- Carboplatin (Paraplatin) patient drug information (Chemocare)[4]
- Carboplatin (Paraplatin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 3/3/1989: Initial approval as palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin. (Based on SWOG 8412 and Swenerton et al. 1992)
Also known as
- Code name: JM8
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Biocarb | Biocarbo | Bioplatinex | Biovinate | Blastocarb | Bonaplatin | Boplatex | Carbo |
| Carbokem | Carbomedac | Carbomerck | Carboplat | Carboplatine | Carboplatino | Carboplatinum | Carbosin |
| Carbotanil | Carbotec | Carbotinol | Careptin | Carplan | Carplanil | Carpsol | Crobextin |
| Cycloplatin | Cycloplatinum | Emorzim | Erbakar | Ercar | Fauldcarbo | Ifacap | Kemocarb |
| Megaplatin | Nealorin | Neocarb | Neocarbo | Oncocarb | Paraplatin | Paraplatine | Pharmaplatin |
| Platamine CS | Platinwas | Ribocarbo | Tecnocarb | Vancel | CBDCA | ||
References
Categories:
- Drugs
- Intravenous medications
- Platinum agents
- Alkylating agents
- Irritant
- Adult T-cell leukemia-lymphoma medications
- Anal cancer medications
- Anaplastic glioma medications
- Bladder cancer medications
- Breast cancer medications
- Carcinoma of unknown primary medications
- Cervical cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Ewing sarcoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Gastric cancer medications
- Glioblastoma medications
- Head and neck cancer medications
- Hodgkin lymphoma medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Medulloblastoma medications
- Melanoma medications
- Malignant pleural mesothelioma medications
- Nasopharyngeal carcinoma medications
- Neuroblastoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- Osteosarcoma medications
- Ovarian cancer medications
- Prostate cancer medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Endometrial cancer medications
- Upper tract urothelial carcinoma medications
- Pancreatic cancer medications (historic)
- FDA approved in 1989
- WHO Essential Cancer Medicine